Match tier Listed
Presence Current · Arkansas
Last published 2024
Sources OpenAlex · ORCID
Refreshed 2026-08-15

Abdul Rafae

Researcher

Also affiliated: McLaren Regional Medical Center (2019–2022); University of Arizona (2018–2020); Lahore University of Management Sciences (2015); Pakistan Army (2019); McLaren Health Care (2022); Benazir Bhutto Hospital (2019); Hamad bin Khalifa University (2015); Arizona Oncology (2018); Michigan State University (2019–2022)

Faculty Researcher

10 h-index 73 pubs 484 cited

  • Humans
  • Hematopoietic Stem Cell Transplantation
  • Multiple Myeloma
  • Lung Neoplasms
  • Antineoplastic Agents
  • Carcinoma, Non-Small-Cell Lung
  • Graft vs Host Disease
  • Transplantation Conditioning
  • Antineoplastic Combined Chemotherapy Protocols
  • Immunosuppression Therapy
  • Neoplasm Recurrence, Local
  • Antibodies, Monoclonal
  • Immunotherapy
  • Anemia
  • Hematologic Diseases

Biography and Research Information

OverviewAI-generated summary

Abdul Rafae's research focuses on hematologic malignancies and solid tumors, with a particular emphasis on therapeutic strategies and their associated toxicities. He has investigated the efficacy and safety of various treatment regimens for multiple myeloma, including carfilzomib-based protocols and bispecific T-cell engagers. His work also extends to non-small cell lung cancer, examining the role of immunotherapy combined with chemotherapy. Rafae has explored less common conditions, such as copper deficiency as a cause of pancytopenia, and reviewed treatment approaches for multicentric Castleman disease. Additionally, his research has addressed the ocular toxicity of specific oncological agents and provided evidence-based recommendations for the treatment of transplant-ineligible multiple myeloma patients. His scholarship metrics include an h-index of 10, with 73 publications and 475 citations.

Metrics

  • h-index: 10
  • Publications: 73
  • Citations: 484

Selected Publications

  • Efficacy and Safety Profile of Blinatumomab in Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R BCP-ALL) in Adults: A Systematic Review of Literature (2024)
    Blood 1 citation DOI OpenAlex
  • A Systematic Review on Efficacy and Safety Profile of Blinatumomab in Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R BCP-ALL) in Children and Young Adults (2024)
    Blood DOI OpenAlex
  • Clinical Outcomes of Lymphoplasmacytic Lymphoma / Waldenstrom Macroglobulinemia (LPL/WM) in the Targeted Therapy Era: A US Multicenter Retrospective Analysis (2024)
    Blood DOI OpenAlex
  • Evidence-Based Recommendations for Induction Treatment of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients; A Scoping Review (2023)
    Blood 2 citations DOI OpenAlex
  • Perspectives on the Treatment of Multiple Myeloma (2023)
    The Oncologist 47 citations DOI OpenAlex
  • Efficacy and Safety of Anti-Amyloid Antibodies in Patients with AL Amyloidosis: A Systematic Review of Literature (2022)
    Blood 1 citation DOI OpenAlex
  • Copper deficiency, a rare but correctable cause of pancytopenia: a review of literature (2022)
    Expert Review of Hematology 19 citations DOI OpenAlex

View all publications on OpenAlex →

Collaboration Network

53 Collaborators 32 Institutions 2 Countries

Top Collaborators

View profile →

Similar Researchers

Based on overlapping research topics